| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[15] Valganciclovir, oral: Roche Products (Pty) Ltd. Valcyte 450 film coated tablet®, South African package insert, 27 July 2012.
Valganciclovir, oral: Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ; Valganciclovir Study Group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002 Apr 11;346(15):1119-26. Erratum in: N Engl J Med 2002 Sep 12;347(11):862. http://www.ncbi.nlm.nih.gov/pubmed/11948271
Valganciclovir, oral (3 months duration): Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009;58(RR-4):1-216. http://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf